Quick Takeaways
- WVE - Wave Life Sciences Ltd. has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: +$227,552,420.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 19 Insiders of Wave Life Sciences Ltd.
- Symbol
- WVE on Nasdaq
- Location
- Singapore, Singapore
What Changed
- Buy value: $246,434,199; sell value: $18,881,779.
- Net share flow: +35,168,256.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$227,552,420.
Buys
$246,434,199
Shares: 36,560,984
Insiders: 5
Sells
$18,881,780
Shares: 1,392,728
Insiders: 11
Net
+$227,552,420
Shares: +35,168,256
Insiders: -6
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 35,089,984 | 33,194 | $218,497,512 | $499,593 | +$217,997,919 |
| 3-6 | 1,471,000 | 1,065,514 | $27,936,688 | $15,546,943 | +$12,389,745 |
| 6-9 | 0 | 258,021 | $0 | $2,574,253 | -$2,574,253 |
| 9-12 | 0 | 35,999 | $0 | $260,991 | -$260,991 |
Wave Life Sciences Ltd. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| GSK plc | 10%+ Owner | $346,668,129 | +$27,930,000 | +8.8% | Filing P/S | 11 Dec 2025 |
| RA Capital Healthcare Fund LP | Director, 10%+ Owner | $175,340,782 | +$54,624,378 | +45% | Filing P/S | 26 Mar 2026 |
| Peter Kolchinsky | Director, 10%+ Owner | $175,340,782 | +$54,624,378 | +45% | Filing P/S | 26 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10%+ Owner | $175,340,782 | +$54,631,065 | +45% | Filing P/S | 26 Mar 2026 |
| Rajeev M. Shah | Director, 10%+ Owner | $175,340,782 | +$54,624,378 | +45% | Filing P/S | 26 Mar 2026 |
| Ken Takanashi | Director | $163,715,967 | -$42,630 | -0.03% | Mixed | 23 Mar 2026 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $5,490,908 | -$43,417 | -0.78% | Filing P/S | 05 Feb 2026 |
| Gregory L. Verdine | Director | $3,866,798 | -$577,961 | -13% | Filing P/S | 08 Dec 2025 |
| Paul Bolno | President and CEO, Director | $3,705,744 | -$2,335,766 | -39% | Filing P/S | 05 Feb 2026 |
| Kyle Moran | Chief Financial Officer | $1,807,478 | -$4,152,238 | -70% | Filing P/S | 05 Feb 2026 |
| Chris Francis | SVP, Corporate Development, Head of Emerging Areas | $928,005 | -$7,102,264 | -88% | Filing P/S | 26 Feb 2026 |
| Erik Ingelsson | Chief Scientific Officer | $637,022 | Median | 09 Apr 2026 | ||
| Heidi L. Wagner | Director | $629,020 | -$189,000 | -23% | Filing P/S | 08 Dec 2025 |
| Mark Corrigan | Director | $405,282 | -$217,297 | -35% | Filing P/S | 08 Dec 2025 |
| Christopher I. Wright | Chief Medical Officer | $330,785 | Median | 09 Apr 2026 | ||
| Aik Na Tan | Director | $323,850 | -$2,027,270 | -86% | Filing P/S | 08 Dec 2025 |
| Henry Christian O | Director | $228,854 | -$1,454,516 | -86% | Filing P/S | 08 Dec 2025 |
| Adrian Rawcliffe | Director | $190,500 | -$739,421 | -80% | Filing P/S | 08 Dec 2025 |
| Michael A. Panzara | Chief Medical Officer, Head of Therapeutics Discovery and Development | Mixed | 25 Jul 2022 |
Top shareholders of Wave Life Sciences Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GSK plc |
3/4/5
13F
|
10%+ Owner · Company |
9.8%
|
18,245,691
|
$346,668,129 | +$27,930,000 | 11 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
3/4/5
|
Company · Director, 10%+ Owner |
17%
from 13D/G
|
18,203,009
|
$309,451,153 | — | 31 Dec 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
2.8%
from 13D/G
|
15,135,983
|
$257,311,705 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.1%
from 13D/G
|
12,648,907
|
$215,031,419 | — | 31 Dec 2025 | |
| Peter Kolchinsky |
3/4/5
|
Director, 10%+ Owner |
15%
|
26,975,505
|
$175,340,782 | +$54,624,378 | 26 Mar 2026 | |
| RA Capital Healthcare Fund LP |
3/4/5
|
Director, 10%+ Owner |
15%
|
26,975,505
|
$175,340,782 | +$54,624,378 | 26 Mar 2026 | |
| Rajeev M. Shah |
3/4/5
|
Director, 10%+ Owner |
15%
|
26,975,505
|
$175,340,782 | +$54,624,378 | 26 Mar 2026 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
5.3%
|
9,786,061
|
$166,363,037 | — | 31 Dec 2025 | |
| Ken Takanashi |
3/4/5
|
Director |
—
mixed-class rows
|
9,706,551
mixed-class rows
|
$163,715,967 | -$42,630 | 23 Mar 2026 | |
| MAVERICK CAPITAL LTD |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
9,280,237
|
$157,764,029 | — | 31 Dec 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
5.4%
|
9,786,061
|
$139,157,787 | -$74,376,843 | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
4%
|
7,407,372
|
$125,927,000 | — | 31 Dec 2025 | |
| Darwin Global Management, Ltd. |
13F
|
Company |
3.9%
|
7,298,421
|
$125,167,920 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.5%
|
6,581,067
|
$111,878,139 | — | 31 Dec 2025 | |
| M28 Capital Management LP |
13F
|
Company |
3.1%
|
5,664,548
|
$96,297,316 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
2.6%
|
4,744,520
|
$80,656,840 | — | 31 Dec 2025 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
2.2%
|
4,095,282
|
$69,619,794 | — | 31 Dec 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
2.2%
|
4,015,000
|
$68,255,000 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
3,573,746
|
$60,753,682 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
3,170,110
|
$53,902,133 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
2,996,084
|
$50,933,428 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
2,854,082
|
$48,519,394 | — | 31 Dec 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
1.5%
|
2,700,000
|
$45,900,000 | — | 31 Dec 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
1.3%
|
2,455,089
|
$41,736,513 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.3%
|
2,450,000
|
$41,650,000 | — | 31 Dec 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
1.2%
|
2,169,105
|
$36,874,785 | — | 31 Dec 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
1.1%
|
2,040,223
|
$34,683,791 | — | 31 Dec 2025 | |
| PFIZER INC |
13F
|
Company |
1%
|
1,875,000
|
$31,875,000 | — | 31 Dec 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
1%
|
1,853,851
|
$31,515,467 | — | 31 Dec 2025 | |
| Bellevue Group AG |
13F
|
Company |
0.8%
|
1,490,518
|
$25,338,806 | — | 31 Dec 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
0.76%
|
1,414,665
|
$24,049,305 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.73%
|
1,350,000
|
$22,950,000 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.64%
|
1,191,361
|
$20,253,137 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.56%
|
1,033,068
|
$17,562,156 | — | 31 Dec 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.54%
|
1,005,984
|
$17,252,626 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.48%
|
892,886
|
$15,179,062 | — | 31 Dec 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.48%
|
883,586
|
$15,020,962 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.43%
|
805,901
|
$13,829,854 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.43%
|
789,964
|
$13,429,388 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.4%
|
749,448
|
$12,740,616 | — | 31 Dec 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.39%
|
722,237
|
$12,278,029 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.32%
|
600,000
|
$10,200,000 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.32%
|
584,633
|
$9,938,761 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.27%
|
500,000
|
$8,500,000 | — | 31 Dec 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.27%
|
492,437
|
$8,371,429 | — | 31 Dec 2025 | |
| Elmind Capital, LP |
13F
|
Company |
0.24%
|
447,846
|
$7,613,382 | — | 31 Dec 2025 | |
| Exome Asset Management LLC |
13F
|
Company |
0.23%
|
421,488
|
$7,165,296 | — | 31 Dec 2025 | |
| Universal- Beteiligungs- und Servicegesellschaft mbH |
13F
|
Individual |
0.22%
|
411,494
|
$6,995,398 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.22%
|
409,663
|
$6,964,277 | — | 31 Dec 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.22%
|
408,166
|
$6,938,822 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Wave Life Sciences Ltd.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 3.73% | $6,312,092 | $6.50 | 971,091 | 26,975,505 | 30 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 10.6% | $16,046,856 | $6.43 | 2,495,623 | 26,004,414 | 27 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| Ra Capital Management, L.P. | WVE | Ordinary Shares | Purchase | 29.2% | $32,265,431 | $6.08 | 5,305,782 | 23,508,791 | 26 Mar 2026 | See footnotes |
| Ken Takanashi | WVE | Ordinary Shares | Conversion of derivative security | 68.4% | 3,901,348 | 9,606,408 | 23 Mar 2026 | See Footnote | ||
| Ken Takanashi | WVE | Series A Preferred Shares | Conversion of derivative security | -100% | -3,901,348 | 0 | 23 Mar 2026 | See Footnote | ||
| Chris Francis | WVE | Ordinary Shares | Sale | -34.9% | $499,593 | $15.05 | -33,194 | 61,867 | 26 Feb 2026 | Direct |
| Chris Francis | WVE | Ordinary Shares | Options Exercise | 71.3% | 33,194 | 79,767 | 26 Feb 2026 | Direct | ||
| Chris Francis | WVE | Share Option (right to buy) | Options Exercise | -35.2% | -33,194 | 61,175 | 26 Feb 2026 | Direct | ||
| Kyle Moran | WVE | Ordinary Shares | Sale | -2.6% | $48,259 | $13.45 | -3,588 | 134,385 | 09 Feb 2026 | Direct |
| Paul Bolno | WVE | Ordinary Shares | Sale | -3.66% | $140,956 | $13.45 | -10,480 | 275,520 | 09 Feb 2026 | Direct |
| Chris Francis | WVE | Ordinary Shares | Sale | -2.95% | $25,326 | $13.45 | -1,883 | 61,867 | 09 Feb 2026 | Direct |
| Chandra Vargeese | WVE | Ordinary Shares | Sale | -0.78% | $43,417 | $13.45 | -3,228 | 408,246 | 09 Feb 2026 | Direct |
| Kyle Moran | WVE | Ordinary Shares | Award | 49.4% | 45,625 | 137,973 | 05 Feb 2026 | Direct | ||
| Kyle Moran | WVE | Share Option (right to buy) | Award | 273,750 | 273,750 | 05 Feb 2026 | Direct | |||
| Paul Bolno | WVE | Ordinary Shares | Award | 136.4% | 165,000 | 286,000 | 05 Feb 2026 | Direct | ||
| Paul Bolno | WVE | Share Option (right to buy) | Award | 1,000,000 | 1,000,000 | 05 Feb 2026 | Direct | |||
| Chris Francis | WVE | Ordinary Shares | Award | 155% | 38,750 | 63,750 | 05 Feb 2026 | Direct | ||
| Chris Francis | WVE | Share Option (right to buy) | Award | 232,500 | 232,500 | 05 Feb 2026 | Direct | |||
| Chandra Vargeese | WVE | Ordinary Shares | Award | 12.5% | 45,625 | 411,474 | 05 Feb 2026 | Direct | ||
| Chandra Vargeese | WVE | Share Option (right to buy) | Award | 273,750 | 273,750 | 05 Feb 2026 | Direct | |||
| Chris Francis | WVE | Ordinary Shares | Sale | -27.3% | $150,260 | $16.03 | -9,375 | 25,000 | 02 Jan 2026 | Direct |
| Chris Francis | WVE | Ordinary Shares | Options Exercise | 37.5% | 9,375 | 34,375 | 02 Jan 2026 | Direct | ||
| Chris Francis | WVE | Share Option (right to buy) | Options Exercise | -100% | -9,375 | 0 | 02 Jan 2026 | Direct | ||
| GSK plc | WVE | Ordinary Shares | Purchase | 8.76% | $27,930,000 | $19.00 | 1,470,000 | 18,245,691 | 11 Dec 2025 | By Corporation |
| Kyle Moran | WVE | Ordinary Shares | Sale | -35.9% | $1,001,979 | $20.03 | -50,036 | 89,218 | 09 Dec 2025 | Direct |
| Kyle Moran | WVE | Ordinary Shares | Options Exercise | 161.6% | 86,000 | 139,218 | 09 Dec 2025 | Direct | ||
| Kyle Moran | WVE | Share Option (right to buy) | Award | -100% | -86,000 | 0 | 09 Dec 2025 | Direct | ||
| Heidi L. Wagner | WVE | Ordinary Shares | Sale | -23.8% | $189,000 | $13.50 | -14,000 | 44,930 | 08 Dec 2025 | Direct |
| Heidi L. Wagner | WVE | Ordinary Shares | Options Exercise | 36.9% | 14,000 | 51,930 | 08 Dec 2025 | Direct | ||
| Heidi L. Wagner | WVE | Share Option (right to buy) | Options Exercise | -66.7% | -14,000 | 7,000 | 08 Dec 2025 | Direct | ||
| Aik Na Tan | WVE | Ordinary Shares | Options Exercise | 119,230 | 70,400 | 08 Dec 2025 | Direct | |||
| Aik Na Tan | WVE | Ordinary Shares | Sale | -84.1% | $1,823,158 | $13.58 | -134,218 | 25,400 | 08 Dec 2025 | Direct |
| Aik Na Tan | WVE | Share Option (right to buy) | Options Exercise | -100% | -119,230 | 0 | 08 Dec 2025 | Direct | ||
| Chris Francis | WVE | Ordinary Shares | Sale | -94.6% | $6,427,085 | $14.57 | -441,031 | 25,000 | 08 Dec 2025 | Direct |
| Chris Francis | WVE | Ordinary Shares | Options Exercise | 441,031 | 147,349 | 08 Dec 2025 | Direct | |||
| Chris Francis | WVE | Share Option (right to buy) | Options Exercise | -100% | -441,031 | 0 | 08 Dec 2025 | Direct | ||
| Kyle Moran | WVE | Ordinary Shares | Sale | -70.2% | $3,102,000 | $14.77 | -210,000 | 89,218 | 08 Dec 2025 | Direct |
| Kyle Moran | WVE | Ordinary Shares | Options Exercise | 210,000 | 189,218 | 08 Dec 2025 | Direct | |||
| Kyle Moran | WVE | Share Option (right to buy) | Award | -100% | -210,000 | 0 | 08 Dec 2025 | Direct | ||
| Gregory L. Verdine | WVE | Ordinary Shares | Sale | -6.77% | $269,461 | $13.47 | -20,000 | 275,217 | 08 Dec 2025 | Direct |
| Adrian Rawcliffe | WVE | Ordinary Shares | Sale | -76.8% | $630,000 | $15.00 | -42,000 | 12,700 | 08 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.